Getting patients started

Start



FOR COMMERCIALLY INSURED PATIENTS

Start your patients through Taltz Together™ or a participating specialty pharmacy and…

THE ENHANCED TALTZ CLEAR ACCESS PROGRAM

Support dollar


*Shipment can be authorized within 2 business days of submitting a prescription to either a participating specialty pharmacy or Taltz Together and commercial insurance is verified; patient enrolls in the Taltz Savings Card program and schedules shipment.

Contingent upon a patient scheduling a delivery with a specialty pharmacy.

Terms and Conditions: Offer good for up to 36 months. $5 Monthly offer subject to a monthly cap and a separate maximum annual benefit of $16,000. $25 Monthly offer subject to a monthly and annual cap of wholesale acquisition cost plus usual and customary pharmacy charges. This offer is invalid for patients without commercial insurance coverage or those whose prescription claims are eligible to be reimbursed, in-whole or in-part, by Medicare Part D, Medicaid, TRICARE or any other state or federal program. Offer void where prohibited by law and subject to change or discontinue without notice. Subject to additional terms and conditions, which can be found here.

§Constitutes that a prior authorization has been submitted.

Accessing Taltz



FOR COMMERCIALLY INSURED PATIENTS

Access Taltz through a specialty pharmacy that is convenient

Support 25-5


Choose a specialty pharmacy that fits prescription process needs

*Government beneficiaries excluded. Terms and conditions apply. See full details above.

Taltz Specialty Pharmacy Network Partners

Enrollment


You can start the enrollment process for your patients using one of the Taltz contracted specialty pharmacies or through Taltz Together™.

Contracted specialty pharmacies


If using a specialty pharmacy, first make sure it is on the list of Taltz contracted specialty pharmacies*. Many specialty pharmacies offer enrollment forms on their website. Submit the completed specialty pharmacy enrollment form or the Taltz enrollment form to one of the contracted specialty pharmacies. If the preferred specialty pharmacy is not included in the Taltz network, submit the enrollment form to Taltz Together for assistance. If you have questions, your Taltz sales representative will be able to assist you.

*To access the list of contracted specialty pharmacies in Puerto Rico, please contact your local sales representative.

List of Contracted Specialty Pharmacies

Taltz Together


To submit to Taltz Together, please fax the completed enrollment form to 1-844-344-8108. Taltz Together will connect patients with the appropriate contracted specialty pharmacy. Patients participating in Taltz Together will be able to choose the support services that best suit their individual needs.


Save


Assuring access so your patients* can confidently get Taltz


*Governmental beneficiaries excluded, subject to terms and conditions.

Support


Taltz together logo

Taltz Together is here to provide the resources and support your patients need. For assistance, call 1-844-TALTZ-NOW (1-844-825-8966) or enroll your patients in Taltz Together by completing the Taltz Together Enrollment Form.


Offerings include:

Taltz support insurance

Insurance Investigation


Support injection training

Injection Training

  • Free of charge to patients and their families
  • Patients can choose either in-person or telephone training
  • Injection training videos available here

Ongoing support

Ongoing Support

  • A personal patient resource to help answer questions or concerns
  • Help is available Monday-Friday from 8 AM to 10 PM ET

Support field reimbursement

Field Reimbursement Support

The Field Reimbursement Manager is an experienced access professional who can help your patients navigate the complex access and reimbursement environment

The managers are

  • Knowledgeable: understand Taltz Together services, access challenges, and affordability options
  • Connected: integrated with the Taltz Together call center and understand the Taltz contracted specialty pharmacy network
  • Patient Focused: committed to providing information to support patient access to Taltz

Support sharps

Sharps Disposal Support

Allows patients to safely dispose of Taltz devices. Once the container is full, your patients can mail it back and contact Taltz Together to receive another one


Indications and Important Safety Information
Indications

Taltz is indicated for your adult patients with active psoriatic arthritis (PsA).

Taltz is also indicated for your adult patients with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Important Safety Information
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease
During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group (Crohn’s disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis.

Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profile observed in patients with psoriatic arthritis was consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis.

Please click to access the Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.
IX HCP ISI 01DEC2017